Table 1.
Demographic and clinical characteristics of the study population.
| Variable | Total (N = 81) | IFX (n = 46) | VEDO (n = 35) |
|---|---|---|---|
| Age, y | 42.7 ± 13.6 | 40.2 ± 12.1 | 45.9 ± 14.8 |
| Sex | |||
| Female | 44 (54.3) | 29 (63.0) | 15 (42.9) |
| Male | 37 (45.7) | 17 (37.0) | 20 (57.1) |
| BMI, kg/m2 | 26.9 ± 7.3 | 27.4 ± 8.2 | 26.2 ± 5.9 |
| IBD diagnosis | |||
| CD | 46 (56.8) | 39 (84.8) | 7 (20.0) |
| UC | 33 (40.7) | 5 (10.9) | 28 (80.0) |
| IBD-U | 2 (2.5) | 2 (4.3) | 0 (0.0) |
| Disease activity | |||
| HBI | 4 (1-6.3) | 4 (1-6) | 4 (1-7) |
| SCCAI | 3 (1-5) | 4 (2-6) | 3 (1-l5) |
| CRP, mg/L | 1.7 (0.8-3.7) | 1.5 (0.7-2.5) | 2.6 (1.1-5.0) |
| Biological trough levels | |||
| Drug level in venous sample, μg/mL | — | 6.5 (3.6-9.1) | 16 (10-24) |
| Antidrug antibodies | |||
| Detectable in venous sample | 4 (4.9) | 1 (2.2) | 3 (3.7) |
Values are mean ± SD, n (%),or median (interquartile range). P values ≤ .05 were considered statistically significant.
Abbreviations: BMI, body mass index; CD, Crohn’s disease; CRP, C-reactive protein; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease unclassified; IFX, infliximab; SCCAI, Simple Clinical Colitis Activity Index; UC, ulcerative colitis; VEDO, vedolizumab.